HEALTHglobal
Apogee strengthens case for longer-lasting eczema drug
Single source
Updated 2 hours ago
First seen March 23, 2026 21:05:37Stay on top of this story
Follow the names and topics behind it.
Add this story's key topics to your watchlist so LyscoNews can highlight related developments and future matches.
Create a free account to sync your watchlist, saved stories, and alerts across devices.
Quick Summary
Company shares climbed by more than 20% on Phase 2 study results suggesting the therapy could provide sustained relief when administered once every three or six months.